PATENT CLAIM ANALYSIS

Application Number: 15890040
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-06
Patent Classification: ["514", "183000"]

Abstract:
The present invention relates to chimeric (including bifunctional) compounds, compositions comprising those compounds and methods of treating cancer in a patient or subject, especially including metastatic cancer where cancer cells exhibit overexpression (heightened expression) of cell surface urokinase-type plasminogen activator receptor (urokinase receptor) compared to normal (non-cancerous) cells. The compounds bind to the urokinase-type plasminogen activator receptor (uPAR) on the surface of a cancer cell, including a metastatic cancer cell, and consequently recruit native antibodies of the patient or subject where the antibodies can selectively degrade and/or deactivate targeted cancer cells through antibody-dependent cellular phagocytosis and antibody-dependent cellular cytotoxicity (ADCC) and/or complement dependent cytotoxicity (CDC) against a large number and variety of cancers, thus providing cancer cell death and an inhibition of growth, elaboration and/or metastasis of the cancer, including remission and cure of the patient's cancer.

Claim (Index 1):
A compound according to the general formula:\n Where   is a moiety which binds to an active site of urokinase-type plasminogen activator receptor (uPAR) on the surface of cancer cells of a patient or subject;  is an antibody binding moiety comprising a hapten which is capable of binding to an antibody in said patient or subject (preferably an endogenous antibody which pre-exists in the patient or subject without having to be raised prior to therapy); Each L1 is a linker molecule which chemically links   to CT, L2 or   in said compound; Each L2 is a linker molecule which chemically links   to CT, L1 or   in a molecule; Each CT is independently an optional connector molecule which, when present links L1 or L2 to  , L1 or L2 to   and L1 to L2; Each j is independently 0, 1, 2, 3, 4 or 5 (preferably 0 or 1, more preferably 1); Each k is independently 0, 1, 2, 3, 4 or 5 (preferably 0 or 1, more preferably 1), with the proviso that at least one CT is present when k and j are both 0 (preferably at least one of k and j is 1); and Each m and n is independently an integer from 1 to 15, 1 to 10, 1 to 5, 1 to 3, 2 to 3, 2 to 5, 1 to 2 or 1 (preferably m is 1 and n is 1, 2 or 3), or a pharmaceutically acceptable salt, solvate or polymorph thereof.

Metadata:
- Claim Count in Document: 104.0
- Percentile: 88.0
- Lexical Diversity: 1.93976
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14397995', '15374272', '13173480', '14480204', '12991926']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7928619571798904
- 35 USC 102 Novelty (BERT): 0.5156764876928357
- Combined Prediction Score: 0.7651434102311849
- Mean Citation Score: 313.007338
- Max Citation Score: 320.29672
- Similarity Product: 256.47538946228025

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test